MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
1.220
0.000
0.00%
After Hours: 1.200 -0.02 -1.63% 19:34 02/23 EST
OPEN
1.210
PREV CLOSE
1.220
HIGH
1.255
LOW
1.200
VOLUME
651.39K
TURNOVER
0
52 WEEK HIGH
3.110
52 WEEK LOW
0.9451
MARKET CAP
109.71M
P/E (TTM)
-0.3931
1D
5D
1M
3M
1Y
5Y
Immunic, Inc. Is Worried About This – Should You Be Worried Too?
TipRanks · 1d ago
Buy Rating Affirmed for Immunic Amid Progress in IMU-838 Trials and Extended Financial Runway
TipRanks · 1d ago
Immunic Releases Insightful Investor Presentation Online
TipRanks · 1d ago
Immunic Q4 EPS $(0.48) Beats $(0.51) Estimate, Cash And Equivalents As Of December 31, 2023 Were $46.7M
Benzinga · 1d ago
Immunic GAAP EPS of -$2.11 misses by $1.60
Immunic, Inc. FY GAAP EPS of -$2.11 misses by $1.60. Shares +1.5% PM. Cash, Cash Equivalents and Investments as of December 31, 2023 were $46.7 million. Earnings are for the quarter ended February 22, 2024.
Seeking Alpha · 1d ago
Immunic's Earnings Outlook
Immunic is set to give its latest quarterly earnings report on Thursday, 2024-02-22. Analysts estimate the company will report an earnings per share of $-0.51. Last quarter the company beat EPS by $0.04. Shares of Immunic were trading at $1.355 as of February 20.
Benzinga · 2d ago
Notable earnings before Thursday's open
Major earnings expected before the bell on Thursday include Dominion Energy (D) and Newmont (NEM) Other major earnings slated for release before Thursday's open include: Old Dominion Energy, Iron Mountain, Newmont and Nikola. The company will report its fourth quarter and full year earnings before the open.
Seeking Alpha · 2d ago
Weekly Report: what happened at IMUX last week (0212-0216)?
Weekly Report · 4d ago
More
About IMUX
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. It is engaged in the clinical development of three orally administered, small molecule programs to address the unmet needs of patients. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (RORyt), an immune cell-specific isoform of RORy; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis (MS), psoriasis and gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.